ReviewVirulence2021
Insights into the molecular determinants involved in
Review in Virulence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- The phosphate specific transport system protein PhoU modulates persister cell formation of Klebsiella pneumoniae.Molecular genetics and genomics : MGG · 2026Article
- Discovery of a multi-epitope tuberculosis vaccine targeting phospholipase C virulence factors: an insilico approach.Biotechnology letters · 2026Article
- TZ1391: a computationally designed circular mRNA multi-epitope vaccine candidate against Mycobacterium tuberculosis via TLR3 immunomodulation.BMC immunology · 2026Article
- A three-phase epidemiological fluctuation framework of extrapulmonary tuberculosis in Fuyang, China: a retrospective study.Frontiers in public health · 2026Article
- Participation of miRNA-23a-3p in Pulmonary Tuberculosis Through Macrophages via the JAK-STAT Pathway.International journal of chronic obstructive pulmonary disease · 2026Article
- Exploring the Protein Landscape of Dormant Mycobacterium tuberculosis Through In Vitro Functional Studies.Advances in experimental medicine and biology · 2026Review
- Netupitant Exhibits Potent Activity onACS infectious diseases · 2025Article
- Exploring the multifaceted roles of resuscitation-promoting factors in tuberculosis: Implications for diagnosis, vaccine development, and drug targeting.Biotechnology reports (Amsterdam, Netherlands) · 2025Review
- Unveiling the properties of ascorbic acid against M. tb through in silico approach: A comparative drug-based study.Journal of molecular modeling · 2025Article
- Assessing the Causal Relationship between Chronic Obstructive Pulmonary Disease and Tuberculosis: A Mendelian Randomization Study.International journal of chronic obstructive pulmonary disease · 2025Article
- Bibliometric and Visualization Analysis of DprE1 Inhibitors to Combat Tuberculosis.Drug design, development and therapy · 2025Article
- A Call to Action: Empowering Pharmacists in Drug-Resistant Tuberculosis Management.Journal of multidisciplinary healthcare · 2025Review
- Physiological stage-dependent effects ofFrontiers in microbiology · 2025Article
- Assessing the propensity of TB clinical isolates to form viable but non-replicating subpopulations.Scientific reports · 2024Article
- Novel Populations ofMicroorganisms · 2024Article
- TargetingACS infectious diseases · 2024Article
- Regulatory role ofFrontiers in microbiology · 2024Article
- Identification of genes associated with persistence inFrontiers in microbiology · 2024Article
- Drug-TolerantInternational journal of molecular sciences · 2023Article
- Synthesis of plant-based, self-adjuvanted, dual antigen specific to Mycobacterium tuberculosis as a novel tuberculosis subunit vaccine that elicits immunogenicity in rabbit.Biotechnology letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The establishment of persistent infections and the reactivation of persistent bacteria to active bacilli are the two hurdles in effective tuberculosis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.